Trial Profile
Effect of glucagon-like peptide 1 (GLP-1) based diabetes medication on blood flow velocity in ischemic stroke patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms EGRABIS1
- 07 Nov 2023 This trial has been discontinued (End Date: 06 May 2023), according to European Clinical Trials Database record.
- 01 Mar 2023 Planned End Date changed from 1 May 2022 to 1 Nov 2023.
- 01 Mar 2023 Planned primary completion date changed from 1 Jan 2022 to 1 Aug 2023.